Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glatiramer Acetate + N-Acetylglucosamine
- Development stage
- Preclinical
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Peptides
- Administration
- Subcutaneous, Oral
01
Overview
This combination involves glatiramer acetate, a synthetic polypeptide used to treat relapsing forms of multiple sclerosis by modifying immune processes, and N-acetylglucosamine, a simple sugar that has shown potential in reducing inflammation and promoting myelin repair in MS patients. Glatiramer acetate is administered subcutaneously, while N-acetylglucosamine is typically taken orally.
02
Targets
MHC II (Major histocompatibility complex class II receptor)MGAT (Mannosyl-glycoprotein N-acetylglucosaminyltransferase)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on Glatiramer Acetate + N-Acetylglucosamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glatiramer Acetate + N-Acetylglucosamine.